Literature DB >> 18831695

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.

Marco Siccardi1, Antonio D'Avolio, Lorena Baietto, Sara Gibbons, Mauro Sciandra, Daniela Colucci, Stefano Bonora, Saye Khoo, David J Back, Giovanni Di Perri, Andrew Owen.   

Abstract

This study investigated pregnane X receptor polymorphisms in relation to unboosted atazanavir plasma concentrations in 2 cohorts of patients. The polymorphism 63396T-->C predicted concentrations below the minimum effective concentration (150 ng/mL) with odds ratios of 18 (P = .008) and 5.13 (P = .02). Prospective studies determining potential clinical usefulness are now warranted.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18831695      PMCID： PMC3672984          DOI： 10.1086/592304

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  17 in total

1.  Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.

Authors:  V A Eagling; D J Back; M G Barry
Journal:  Br J Clin Pharmacol       Date:  1997-08       Impact factor: 4.335

2.  Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Authors:  Sara Colombo; Thierry Buclin; Matthias Cavassini; Laurent A Décosterd; Amalio Telenti; Jérôme Biollaz; Chantal Csajka
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  The impact of host pharmacogenetics on antiretroviral drug disposition.

Authors:  Andrew Owen
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 4.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

5.  Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

Authors:  Jennifer Ford; Marta Boffito; Desmond Maitland; Andrew Hill; David Back; Saye Khoo; Mark Nelson; Graeme Moyle; Brian Gazzard; Anton Pozniak
Journal:  J Antimicrob Chemother       Date:  2006-09-19       Impact factor: 5.790

6.  Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

Authors:  Sonia Rodríguez Nóvoa; Pablo Barreiro; Ana Rendón; Ana Barrios; Angélica Corral; Inmaculada Jiménez-Nacher; Juan González-Lahoz; Vincent Soriano
Journal:  Clin Infect Dis       Date:  2005-12-08       Impact factor: 9.079

7.  Pharmacogenetics of HIV therapy.

Authors:  Andrew Owen; Munir Pirmohamed; Saye H Khoo; David J Back
Journal:  Pharmacogenet Genomics       Date:  2006-10       Impact factor: 2.089

8.  Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4.

Authors:  E Hustert; A Zibat; E Presecan-Siedel; R Eiselt; R Mueller; C Fuss; I Brehm; U Brinkmann; M Eichelbaum; L Wojnowski; O Burk
Journal:  Drug Metab Dispos       Date:  2001-11       Impact factor: 3.922

9.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.

Authors:  J M Lehmann; D D McKee; M A Watson; T M Willson; J T Moore; S A Kliewer
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

10.  Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells.

Authors:  P Martin; R Riley; D J Back; A Owen
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739
View more
  31 in total

1.  Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.

Authors:  Alessandro Schipani; Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Marco Simiele; Stefano Bonora; Sonia Rodríguez Novoa; Lorena Cuenca; Vincent Soriano; Nitipatana Chierakul; Natpratou Saguenwong; Charoen Chuchuttaworn; Janelle M Hoskins; Anne M Dvorak; Howard L McLeod; Gerry Davies; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.

Authors:  Rubin Lubomirov; Sara Colombo; Julia di Iulio; Bruno Ledergerber; Raquel Martinez; Matthias Cavassini; Bernard Hirschel; Enos Bernasconi; Luigia Elzi; Pietro Vernazza; Hansjakob Furrer; Huldrych F Günthard; Amalio Telenti
Journal:  J Infect Dis       Date:  2010-12-09       Impact factor: 5.226

3.  Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.

Authors:  Tim R Cressey; Rohan Hazra; Andrew Wiznia; Marc Foca; Patrick Jean-Philippe; Bobbie Graham; Jennifer R King; Paula Britto; Vincent J Carey; Edward P Acosta; Ram Yogev
Journal:  Pediatr Infect Dis J       Date:  2016-12       Impact factor: 2.129

4.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

5.  PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria Alvarellos; Chantal Guillemette; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-05       Impact factor: 2.089

6.  The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

Authors:  Emmanuel Chigutsa; Marianne E Visser; Elizabeth C Swart; Paolo Denti; Sudeep Pushpakom; Deirdre Egan; Nicholas H G Holford; Peter J Smith; Gary Maartens; Andrew Owen; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

7.  Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.

Authors:  Daniel H Johnson; Charles Venuto; Marylyn D Ritchie; Gene D Morse; Eric S Daar; Paul J McLaren; David W Haas
Journal:  Pharmacogenet Genomics       Date:  2014-04       Impact factor: 2.089

8.  HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

Authors:  Ruben C Hartkoorn; Wai San Kwan; Victoria Shallcross; Ammara Chaikan; Neill Liptrott; Deirdre Egan; Enrique Salcedo Sora; Chloë E James; Sara Gibbons; Pat G Bray; David J Back; Saye H Khoo; Andrew Owen
Journal:  Pharmacogenet Genomics       Date:  2010-02       Impact factor: 2.089

9.  Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

Authors:  Peter L Anderson; Christina L Aquilante; Edward M Gardner; Julie Predhomme; Patrick McDaneld; Lane R Bushman; Jia-Hua Zheng; Michelle Ray; Samantha MaWhinney
Journal:  J Antimicrob Chemother       Date:  2009-08-26       Impact factor: 5.790

10.  Population pharmacokinetic study of memantine: effects of clinical and genetic factors.

Authors:  Muriel Noetzli; Monia Guidi; Karsten Ebbing; Stephan Eyer; Laurence Wilhelm; Agnès Michon; Valérie Thomazic; Abdel-Messieh Alnawaqil; Sophie Maurer; Serge Zumbach; Panteleimon Giannakopoulos; Armin von Gunten; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.